Get started
Author

Yeun Mi Yim

Assessment of costs associated with adverse events in patients with cancer
2018 · William Wong, Yeun Mi Yim, et al. · PLoS ONE · 168
PDF
Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study
2014 · Charles S. Cleeland, Musa Mayer, et al. · The Breast · 75
Age distribution of patients with advanced non-melanoma skin cancer in the United States
2013 · Stacey Dacosta Byfield, Diana Chen, et al. · Archives of Dermatological Research · 65
PDF
Survival Outcomes of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Treated in US Community Oncology
2012 · Thomas H. Cartwright, Yeun Mi Yim, et al. · Clinical Colorectal Cancer · 38
Assessing Health-Related Quality of Life for Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome
2013 · Susan D. Mathias, Mary-Margaret Chren, et al. · JAMA Dermatology · 33
Differences in Health Care Use and Costs Among Patients With Cancer Receiving Intravenous Chemotherapy in Physician Offices Versus in Hospital Outpatient Settings
2017 · Maxine D. Fisher, Rajeshwari Punekar, et al. · Journal of Oncology Practice · 30
PDF
Comparative healthcare costs in patients with metastatic melanoma in the USA
2015 · Chun-Lan Chang, Vernon F. Schabert, et al. · Melanoma Research · 27
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study
2018 · Johan Hansson, Karen Bartley, et al. · European Journal of Dermatology · 26
Treatment patterns and outcomes in BRAF V600E‐mutant melanoma patients with brain metastases receiving vemurafenib in the real‐world setting
2015 · Geoffrey T. Gibney, Geneviève Gauthier, et al. · Cancer Medicine · 24
PDF
Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy
2018 · Hossein Borghaei, Yeun Mi Yim, et al. · Lung Cancer · 18
Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer
2012 · Mark S Walker, Elaine Yu Pharm, et al. · BMC Research Notes · 16
PDF
Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients
2011 · Mark S Walker, Murad Hasan, et al. · Health and Quality of Life Outcomes · 16
PDF
Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non–Small-Cell Lung Cancer
2019 · Joshua T. Cohen, Pei-Jung Lin, et al. · Journal of Oncology Practice · 15
Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer
2012 · Veena Shankaran, David Mummy, et al. · Clinical Colorectal Cancer · 15
Reliability and validity of the Advanced Basal Cell Carcinoma Index (aBCCdex)
2015 · S.D. Mathias, M.M. Chren, et al. · British Journal of Dermatology · 13
Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer
2011 · Hongbo Yang, Andrew P. Yu, et al. · Journal of Medical Economics · 11
PDF
Characterization and survival of patients with metastatic basal cell carcinoma in the Department of Veterans Affairs: a retrospective electronic health record review
2018 · Vanessa W. Stevens, David D. Stenehjem, et al. · Archives of Dermatological Research · 6
Patient-reported outcomes (PRO) in patients with metastatic breast cancer (MBC) from the VIRGO observational cohort study (OCS).
2012 · Peter Andrew Kaufman, Musa Mayer, et al. · Journal of Clinical Oncology · 4
Biomarker testing, treatment (Tx) and survival outcomes in Medicaid compared to commercially insured (CI) patients with advanced NSCLC (aNSCLC).
2019 · Yeun Mi Yim, Ning Wu, et al. · Journal of Clinical Oncology · 3
Patient-reported outcomes (PRO) in patients with metastatic breast cancer (MBC) from the VIRGO observational cohort study (OCS).
2012 · Peter Andrew Kaufman, Musa Mayer, et al. · Journal of Clinical Oncology · 3
3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study
2015 · J. Hansson, K. Bartley, et al. · European Journal of Cancer · 2
Comparative health care (HC) costs in patients (pts) with metastatic melanoma (mM).
2014 · Chun-Lan Chang, Yeun Mi Yim, et al. · Journal of Clinical Oncology · 2
Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
2014 · Geoffrey Thomas Gibney, Maryna Marynchenko, et al. · Journal of Clinical Oncology · 2
Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC)
2016 · Y.M. Yim, M. Gandhi, et al. · Annals of Oncology · 1
Comparative health care (HC) costs and quality of care in five cancer types by physician office (PO) and hospital outpatient (HOP) settings.
2014 · Maxine Fisher, Yeun Mi Yim, et al. · Journal of Clinical Oncology · 1
Works count: 41
Citation count: 617
H-index: 14
I10-index: 16
Year
Topic
Type